BOSTON (TheStreet) -- It's report card time. I've been going back over a year's worth of biotech columns to assess my hits and misses for 2014.
Contradicting my reputation as a single-minded biotech stock "basher," I did well with bullish calls this year.
My prediction for a positive outcome from the traffic/transport studies of Vertex Pharma's (VRTX) cystic fibrosis combination therapy: Nailed. My subsequent explanation for why Vertex could still be considered undervalued. Correct.
I preached patience and faith in Chelsea Therapeutics' ability to convince an FDA advisory panel to recommend the approval of Northera. Sure enough, Chelsea got the positive vote it sought as the FDA approved Northera and then Chelsea was acquired by Lundbeck. Home run.